利妥昔单抗诱导胃黏膜相关淋巴组织淋巴瘤缓解

Rituximab-induced remission of a gastric MALT lymphoma.

作者信息

Datta Yvonne H, Kampalath Bal, Binion David G

机构信息

Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.

出版信息

Leuk Lymphoma. 2004 Jun;45(6):1297-9. doi: 10.1080/1042819032000159889.

DOI:10.1080/1042819032000159889

PMID:15360017

Abstract

Gastric MALT lymphoma is usually associated with H. pylori infection, and responds to treatment with antibiotics and a proton pump inhibitor. We report a case of H. pylori negative gastric MALT lymphoma. The patient was followed conservatively for 2 years until she developed gastrointestinal bleeding with significant anemia. She was treated with rituximab 375 mg/m2 weekly for four doses, which resulted in a biopsy proven complete remission. Rituximab therapy is a reasonable, well tolerated treatment alternative for MALT lymphomas not associated with H. pylori.

摘要

胃黏膜相关淋巴组织淋巴瘤通常与幽门螺杆菌感染有关，对抗生素和质子泵抑制剂治疗有反应。我们报告一例幽门螺杆菌阴性的胃黏膜相关淋巴组织淋巴瘤病例。该患者保守随访2年，直至出现伴有严重贫血的胃肠道出血。她接受了利妥昔单抗治疗，剂量为375mg/m²，每周一次，共四剂，活检证实达到完全缓解。对于与幽门螺杆菌无关的黏膜相关淋巴组织淋巴瘤，利妥昔单抗治疗是一种合理且耐受性良好的治疗选择。